CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 245 enrolled
Drug / intervention
bepotastine besilate ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01174823
NCT01174823Phase 2Completed

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

Bausch & Lomb Incorporated·interventional·Posted Aug 4, 2010·Updated Sep 14, 2020

In Brief

A Phase 2 clinical trial evaluating bepotastine besilate ophthalmic solution and placebo comparator ophthalmic solution for Allergic Conjunctivitis. Completed, enrolled 245 participants across 1 site.

Detailed Summary

The purpose of this study is to study the safety and efficacy of bepotastine besilate ophthalmic solution in allergic conjunctivitis patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 4, 2010
Enrollment StartJun 1, 2010
Primary CompletionOct 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.9 years ago

Interventions

bepotastine besilate ophthalmic solutiondrug

sterile ophthalmic solution

placebo comparator ophthalmic solutiondrug

sterile ophthalmic solution